p.83 抽出テキスト

337. Tattevin P, Boutoille D, Vitrat V, Van Grunderbeeck N, Revest M, Dupont M, et al. Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study. J Antimicrob Chemother 2014;69:2010–2013. https:// doi.org/10.1093/jac/dku085 338. Vouillamoz J, Entenza JM, Feger C, Glauser MP, Moreillon P. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 2000;44:1789–1795. https://doi.org/10. 1128/AAC.44.7.1789-1795.2000 339. Guignard B, Entenza JM, Moreillon P. Beta-lactams against methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol 2005;5:479–489. https://doi.org/10.1016/j. coph.2005.06.002 340. Jang H-C, Kim S-H, Kim KH, Kim CJ, Lee S, Song K-H, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009;49:395–401. https://doi.org/10.1086/ 600295 341. Perichon B, Courvalin P. Synergism between beta-lactams and glycopeptides against vana-type methicillin-resistant Staphylococcus aureus and heterologous expression of the vanA operon. Antimicrob Agents Chemother 2006;50:3622–3630. https://doi.org/ 10.1128/AAC.00410-06 342. Casalta JP, Zaratzian C, Hubert S, Thuny F, Gouriet F, Habib G, et al. Treatment of Staphylococcus aureus endocarditis with high doses of trimethoprim/sulfamethoxazole and clindamycin-preliminary report. Int J Antimicrob Agents 2013;42:190–191. https:// doi.org/10.1016/j.ijantimicag.2013.05.002 343. Tissot-Dupont H, Gouriet F, Oliver L, Jamme M, Casalta JP, Jimeno MT, et al. High-dose trimethoprim-sulfamethoxazole and clindamycin for Staphylococcus aureus endocarditis. Int J Antimicrob Agents 2019;54:143–148. https://doi.org/10.1016/j. ijantimicag.2019.06.006 344. Lefevre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, et al. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study. Eur J Clin Microbiol Infect Dis 2021;40:2605–2616. https://doi.org/10.1007/s10096- 021-04313-3 345. Jorgensen SCJ, Zasowski EJ, Trinh TD, Lagnf AM, Bhatia S, Sabagha N, et al. Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. Clin Infect Dis 2020;71:1–10. https://doi.org/10.1093/cid/ciz746 346. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004; 48:2871–2875. https://doi.org/10.1128/AAC.48.8.2871-2875.2004 347. Berti AD, Wergin JE, Girdaukas GG, Hetzel SJ, Sakoulas G, Rose WE. Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics. Antimicrob Agents Chemother 2012;56: 5046–5053. https://doi.org/10.1128/AAC.00502-12 348. Sakoulas G, Moise PA, Casapao AM, Nonejuie P, Olson J, Okumura CY, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014;36:1317–1333. https://doi.org/10.1016/j. clinthera.2014.05.061 349. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, et al. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother 2012;56:5296–5302. https://doi.org/10.1128/AAC.00797-12 350. Chirouze C, Athan E, Alla F, Chu VH, Ralph Corey G, Selton-Suty C, et al. Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-prospective cohort study. Clin Microbiol Infect 2013; 19:1140–1147. https://doi.org/10.1111/1469-0691.12166 351. Prematunge C, MacDougall C, Johnstone J, Adomako K, Lam F, Robertson J, et al. Vre and vse bacteremia outcomes in the era of effective vre therapy: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 2016;37:26–35. https://doi.org/10. 1017/ice.2015.228 352. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327–333. https://doi.org/ 10.1086/430909 353. Lupia T, Roberto G, Scaglione L, Shbaklo N, De Benedetto I, Scabini S, et al. Clinical and microbiological characteristics of bloodstream infections caused by Enterococcus spp. within internal medicine wards: a two-year single-centre experience. Intern Emerg Med 2022;17:1129–1137. https://doi.org/10.1007/s11739-022-02926-w 354. Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC bacteraemia resistance surveillance programme. J Antimicrob Chemother 2004;53:1018–1032. https://doi.org/10.1093/jac/dkh232 355. Pericas JM, Cervera C, del Rio A, Moreno A, Garcia de la Maria C, Almela M, et al. Changes in the treatment of Enterococcus faecalis infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. Clin Microbiol Infect 2014;20:O1075–O1083. https://doi.org/10.1111/1469-0691.12756 356. Rottier WC, Pinholt M, van der Bij AK, Arpi M, Blank SN, Nabuurs-Franssen MH, et al. Attributable mortality of vancomycin resistance in ampicillin-resistant Enterococcus faecium bacteremia in Denmark and the Netherlands: a matched cohort study. Infect Control Hosp Epidemiol 2022;43:719–727. https://doi.org/10.1017/ice.2021.216 357. Pinholt M, Gumpert H, Bayliss S, Nielsen JB, Vorobieva V, Pedersen M, et al. Genomic analysis of 495 vancomycin-resistant enterococcus faecium reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark. J Antimicrob Chemother 2017;72:40–47. https://doi.org/10.1093/jac/dkw360 358. Taji A, Heidari H, Shahini-Shamsabadi M, Motamedifar M. High-level resistance to aminoglycosides among multidrug resistant non-faecalis and non-faecium enterococci. Clin Lab 2022;68. https://doi.org/10.7754/Clin.Lab.2022.220222 359. Manoharan H, Lalitha AKV, Mariappan S, Sekar U, Venkataramana GP. Molecular characterization of high-level aminoglycoside resistance among enterococcus species. J Lab Physicians 2022;14:290–294. https://doi.org/10.1055/s-0042-1742423 360. Fernandez-Hidalgo N, Almirante B, Gavalda J, Gurgui M, Pena C, de Alarcon A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis 2013;56:1261–1268. https://doi.org/10.1093/cid/cit052 361. Gavalda J, Len O, Miro JM, Munoz P, Montejo M, Alarcon A, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007;146:574–579. https://doi.org/10.7326/0003-4819-146-8- 200704170-00008 362. Miro JM, Pericas JM, del Rio A; Hospital Clinic Endocarditis Study Group. A new era for treating Enterococcus faecalis endocarditis: ampicillin plus short-course gentamicin or ampicillin plus ceftriaxone: that is the question!. Circulation 2013;127:1763–1766. https://doi.org/10.1161/CIRCULATIONAHA.113.002431 363. Olaison L, Schadewitz K; Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002;34:159–166. https://doi.org/10.1086/338233 364. De Nadai T, Francois M, Sommet A, Dubois D, Metsu D, Grare M, et al. Efficacy of teicoplanin monotherapy following initial standard therapy in Enterococcus faecalis infective endocarditis: a retrospective cohort study. Infection 2019;47:463–469. https:// doi.org/10.1007/s15010-019-01290-w 365. Escola-Verge L, Fernandez-Hidalgo N, Rodriguez-Pardo D, Pigrau C, Gonzalez-Lopez JJ, Bartolome R, et al. Teicoplanin for treating enterococcal infective endocarditis: a retrospective observational study from a referral centre in Spain. Int J Antimicrob Agents 2019;53:165–170. https://doi.org/10.1016/j.ijantimicag.2018.10.003 366. Herrera-Hidalgo L, Lomas-Cabezas JM, Lopez-Cortes LE, Luque-Marquez R, Lopez-Cortes LF, Martinez-Marcos FJ, et al. Ampicillin plus ceftriaxone combined therapy for Enterococcus faecalis infective endocarditis in OPAT. J Clin Med 2021;11:7. https://doi.org/10.3390/jcm11010007 367. Herrera-Hidalgo L, Lopez-Cortes LE, Luque-Marquez R, Galvez-Acebal J, de Alarcon A, Lopez-Cortes LF, et al. Ampicillin and ceftriaxone solution stability at different temperatures in outpatient parenteral antimicrobial therapy. Antimicrob Agents Chemother 2020;64:e00309-20. https://doi.org/10.1128/AAC.00309-20 368. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant enterococcus bacteremia. Clin Infect Dis 2008;46:30–36. https://doi.org/10.1086/523588 369. Wang JT, Yang CJ, Yang JL, Lin SW, Chuang YC, Sheng WH, et al. A high daptomycin dose is associated with better bacterial clearance in infections caused by vancomycinresistant enterococcus faecium regardless of daptomycin minimum inhibitory concentration in a rat infective endocarditis model. Microbiol Spectr 2022;10:e0255122. https://doi.org/10.1128/spectrum.02551-22 370. Blackberg A, Morenius C, Olaison L, Berge A, Rasmussen M. Infective endocarditis caused by HACEK group bacteria–a registry-based comparative study. Eur J Clin Microbiol Infect Dis 2021;40:1919–1924. https://doi.org/10.1007/s10096-021-04240-3 371. Paturel L, Casalta JP, Habib G, Nezri M, Raoult D. Actinobacillus actinomycetemcomitans endocarditis. Clin Microbiol Infect 2004;10:98–118. https://doi.org/10.1111/j.1469- 0691.2004.00794.x 372. Das M, Badley AD, Cockerill FR, Steckelberg JM, Wilson WR. Infective endocarditis caused by HACEK microorganisms. Annu Rev Med 1997;48:25–33. https://doi.org/ 10.1146/annurev.med.48.1.25 373. Chambers ST, Murdoch D, Morris A, Holland D, Pappas P, Almela M, et al. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. PLoS One 2013;8:e63181. https://doi.org/10.1371/journal.pone.0063181 374. Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, et al. Non-HACEK Gram-negative bacillus endocarditis. Ann Intern Med 2007;147: 829–835. https://doi.org/10.7326/0003-4819-147-12-200712180-00002 375. Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L. Clinical outcomes of combination versus monotherapy for Gram negative non-HACEK infective endocarditis. Diagn Microbiol Infect Dis 2021;101:115504. https://doi.org/10.1016/j.diagmicrobio. 2021.115504 Downloaded from academic.oup.com/eurheartj/article/44/39/3948/7243107 by guest on 07 October 2026